BRIEF published on 01/08/2026 at 18:05, 2 months 14 days ago THX Pharma publie une lettre aux actionnaires Biopharmaceutique Communication Aux Actionnaires Développement De Médicaments Maladies Neurologiques THX Pharma
BRIEF published on 01/08/2026 at 18:05, 2 months 14 days ago Publication of the letter to shareholders by Theranexus Shareholders Neuroscience Rare Diseases Theranexus Drugs
BRIEF published on 01/08/2026 at 18:05, 2 months 14 days ago THX Pharma Releases Shareholder Letter Drug Development Biopharmaceutical Shareholder Communication Neurological Diseases THX Pharma
BRIEF published on 01/08/2026 at 18:05, 2 months 14 days ago Publication de la lettre aux actionnaires par Theranexus Actionnaires Médicaments Maladies Rares Theranexus Neurosciences
PRESS RELEASE published on 01/08/2026 at 18:00, 2 months 14 days ago THX Pharma announces the publication of its letter to shareholders THX Pharma (Theranexus) announces the publication of its letter to shareholders, highlighting treatments for rare neurological diseases and upcoming drug commercialization. Forward-looking statements included Forward-looking Statements Theranexus Neurological Diseases THX Pharma Drug Commercialization
PRESS RELEASE published on 01/08/2026 at 18:00, 2 months 14 days ago THX Pharma annonce la publication de sa lettre aux actionnaires Theranexus annonce la publication de sa lettre aux actionnaires. THX Pharma se spécialise dans le traitement des maladies neurologiques rares. Plus d'infos sur leur site Actionnaires Newsletter Theranexus Maladies Neurologiques Rares THX Pharma
BRIEF published on 01/07/2026 at 08:05, 2 months 15 days ago THX Pharma appoints Julien Veys as Deputy General Manager Business Strategy Appointment THX Pharma Julien Veys Neurological Medications
BRIEF published on 01/07/2026 at 08:05, 2 months 15 days ago THX Pharma nomme Julien Veys au poste de Directeur général adjoint Nomination Stratégie Commerciale THX Pharma Julien Veys Médicaments Neurologiques
BRIEF published on 01/07/2026 at 08:05, 2 months 15 days ago THX Pharma Names Julien Veys as Deputy CEO Rare Neurological Diseases THX Pharma Julien Veys Appointment Theranexus Strategy Pharmaceutical Commercialization
BRIEF published on 01/07/2026 at 08:05, 2 months 15 days ago THX Pharma nomme Julien Veys au poste de directeur général adjoint Maladies Neurologiques Rares THX Pharma Nomination De Julien Veys Stratégie Theranexus Commercialisation Pharmaceutique
Published on 03/20/2026 at 13:30, 2 days 6 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 7 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 7 hours 7 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 20 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 22 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 22 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 1 hour ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 1 hour ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
